Clinical Efficacy of oral Fosfomycin Trometamol and Cefixime in the Treatment of Acute Bacterial Prostatitis (CEFOSPROST): a comparative, randomized, open, multicenter trial.

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-513465-39-00

Acronym

CEFOSPROST

Enrollment

276

Registered

2024-08-21

Start date

2024-12-04

Completion date

Unknown

Last updated

2025-11-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute bacterial prostatitis

Brief summary

Clinical cure: patient alive with reduction of all initial local and systemic febrile UTI related symptoms and without additional systemic antibiotic therapy for UTI (except antibiotic prophylaxis) at 6-10 days post-end of treatment.

Interventions

DRUGCEFIXIME

DRUGCIPROFLOXACIN HYDROCHLORIDE

DRUGFOSFOMYCIN

Eligibility

Sex/Gender

Male

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Clinical cure: patient alive with reduction of all initial local and systemic febrile UTI related symptoms and without additional systemic antibiotic therapy for UTI (except antibiotic prophylaxis) at 6-10 days post-end of treatment.	—

Countries

Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026